首页> 美国卫生研究院文献>Clinical and Diagnostic Laboratory Immunology >Recombinant GRA4 or ROP2 Protein Combined with Alum or the gra4 Gene Provides Partial Protection in Chronic Murine Models of Toxoplasmosis
【2h】

Recombinant GRA4 or ROP2 Protein Combined with Alum or the gra4 Gene Provides Partial Protection in Chronic Murine Models of Toxoplasmosis

机译:重组GRA4或ROP2蛋白与明矾或gra4基因结合在弓形虫病的慢性小鼠模型中提供部分保护

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The efficacy of vaccination with Toxoplasma gondii recombinant GRA4 (rGRA4) and ROP2 (rRPO2) proteins and a mix of both combined with alum were evaluated in C57BL/6 and C3H mice. In C57BL/6 mice, rGRA4 and rGRA4-rROP2 immunizations generated similar levels of immunoglobulin G1 (IgG1) and IgG2a isotypes against GRA4, whereas immunizations with rROP2 and the mix induced a predominant IgG1 production against ROP2. All groups of C3H vaccinated mice exhibited higher levels of IgG1 than IgG2a. rGRA4-stimulated splenocytes from vaccinated mice produced primarily gamma interferon while those stimulated with rROP2 produced interleukin-4. Challenge of rGRA4- or rGRA4-rROP2-vaccinated mice from both strains with ME49 cysts resulted in fewer brain cysts than the controls, whereas vaccination with rROP2 alone only conferred protection to C3H mice. Immunization with a plasmid carrying the entire open reading frame of GRA4 showed a protective level similar to that of rGRA4 combined with alum. These results suggest that GRA4 can be a good candidate for a multiantigen anti-T. gondii vaccine based on the use of alum as an adjuvant.
机译:在C57BL / 6和C3H小鼠中评估了弓形虫重组GRA4(rGRA4)和ROP2(rRPO2)蛋白以及二者与明矾的混合物的疫苗接种效果。在C57BL / 6小鼠中,rGRA4和rGRA4-rROP2免疫产生了类似水平的针对GRA4的免疫球蛋白G1(IgG1)和IgG2a同种型,而用rROP2和混合物进行的免疫则主要产生了针对ROP2的IgG1产生。接种C3H的所有小鼠组均比IgG2a表现出更高的IgG1水平。来自接种疫苗的小鼠的rGRA4刺激的脾细胞主要产生γ干扰素,而被rROP2刺激的那些细胞产生白介素4。来自两种品系的具有ME49囊肿的rGRA4-或rGRA4-rROP2疫苗接种小鼠的攻击导致的脑囊肿少于对照组,而单独接种rROP2疫苗仅对C3H小鼠提供保护。用带有GRA4完整开放阅读框的质粒免疫显示出类似于rGRA4与明矾结合的保护水平。这些结果表明,GRA4可以作为多抗原抗T的良好候选者。基于明矾作为佐剂的刚迪疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号